Tumor-infiltrating lymphocytes (TILs) play a crucial role in regulating tumor progression, with T cells traditionally receiving the most attention. However, recent studies have highlighted the significant contribution of B cells to anti-tumor immunity.
Research indicates that high densities of B cells and elevated antibody levels correlate with improved prognoses in various human cancers, including soft tissue sarcomas.
The fundamental question arises: can novel strategies be designed to effectively harness these cells for immunotherapeutic purposes?
At Takis, Eugenia Principato, as part of the Rome Technopole project, employs single-cell technology to analyze intratumoral B cells, identifying promising immunoglobulin repertoires for novel cancer immunotherapies.
Our team successfully identified lymphocytic infiltrates in murine sarcoma and carcinoma mouse models, affirming the feasibility of characterizing lymphocytes in vivo. Additionally, we have validated protocols for B cell identification using the CellCelector system.
We aim to contribute to a deeper understanding of B cell functions in the tumor microenvironment, shedding light on their response to therapy and potential as therapeutic targets.
Check out our poster for more information!
#pharma #pharmaceutical g#biotech #biotechnology #research
